FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1 is selected from C1-6 alkylthio, 5–6-member heteroaryl containing 1 or 2 heteroatoms, C2-6-alkynyl, C3-6 - cycloalkyl, each of which is optionally substituted with 1, 2 or 3 R; T1 is selected from N or CH; T2 is selected from N or C (R2); R2 is selected from H, F, Cl, Br, I; R3 is selected from H, halogen or C1-6-alkyl, each of which is optionally substituted with 1, 2 or 3 R depending on R1, wherein the number of heteroatoms or heteroatomic groups is independently independently selected from 1 or 2. Invention also relates to individual compounds, isomers and stereoisomers thereof and pharmaceutically acceptable salts thereof, as well as to use thereof in preparing a medicament for treating diseases associated with influenza viruses.
EFFECT: technical result consists in obtaining compounds for preventing and treating epidemic influenza caused by influenza A virus, and epidemic influenza caused by highly pathogenic avian influenza viruses having high safety, good oral bioavailability.
21 cl, 8 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
SPIRO COMPOUNDS AS ERK INHIBITORS AND THEIR USE | 2020 |
|
RU2800042C1 |
THIAZOLACTAM COMPOUNDS AS ERK INHIBITORS AND THEIR APPLICATIONS | 2020 |
|
RU2805569C1 |
PYRIDOPYRIMIDINE COMPOUNDS ACTING AS DOUBLE INHIBITORS OF mTORC 1/2 | 2018 |
|
RU2771201C2 |
MACROCYCLIC COMPOUND WITH FUNCTIONS OF WEE1 INHIBITOR AND ITS APPLICATION OPTIONS | 2018 |
|
RU2783243C2 |
S1P1 AGONIST AND ITS APPLICATION | 2017 |
|
RU2754845C2 |
PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-RK INHIBITORS | 2020 |
|
RU2796163C1 |
FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
PDE4 INHIBITOR | 2017 |
|
RU2743126C2 |
CRYSTALLINE FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND A CORRESPONDING METHOD OF PRODUCING | 2019 |
|
RU2769050C1 |
ATR INHIBITOR AND ITS USE | 2019 |
|
RU2799047C2 |
Authors
Dates
2020-07-23—Published
2017-09-05—Filed